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Coal and biomass serves as a major
fuel source for50% of the world’s pop-
ulation.1 In Colombia the prevalence of
wood-smoke exposure (WSE) in areas
having less economic development is
around 24%. The amount of pollution due
to wood-smoke (WS) is elevated; more-
over, it has been calculated that cooking
with wood for 3 h/d, exposes people to
similar amounts of benzo-pyrene as smok-
ing 3 packs of cigarettes/d.1,2 This con-
firms, at least in part, that carcinogens
present in WS are similar to those asso-
ciated with tobacco. There is biologic
plausibility for the association of WSE
and non-small cell lung cancer because
of a similar effect on p53, phospho-p53,
and MDM2 protein expression as occurs
in tobacco smokers.3 Another’s, have
shown an abnormal GSTP-1 genotype,
matrix metalloproteinase expression,
and DNA adduct formation.4
In a previous issue of the JTO,
Arrieta et al.5 described the results of 42
non-small cell lung cancer patients who
were being treated with erlotinib and
had been exposed to WS for approxi-
mately 40 years; 14% of these subgroup
patients had been smokers, overall re-
sponse rate was 34% and clinical benefit
was 67%. Histologic subtype and WSE
were the variables positively influencing
erlotinib response. The study also
showed that the independent factor
which most affected progression-free
survival (PFS) and overall survival was
WSE, and a mean of 17.6 and 19.2
months has being found for each of
these outcomes, respectively. Neverthe-
less, response rate to erlotinib among
smokers was strikingly high (19%), 16%
of the subjects included had stage IIIB
disease and PFS rate for patients with
WSE curiously proved to be greater than
in patients having epidermal growth fac-
tor receptor mutations. Mean follow-up
time was short (4.5 months) and possi-
ble confusion variables (mutational pro-
file, smoking history, comorbidity) were
not suitably debugged.
These findings go against the
scientific aphorisms used for predict-
ing epidermal growth factor receptor-
tyrosine kinase inhibitors response in
patients suffering from lung adenocar-
cinoma, thereby supporting a theory
regarding an alternative route for tu-
mors being produced by WSE. The
main outcomes in a series of 156 pa-
tients suffering from lung adenocarci-
noma treated in Bogota´ (Colombia)
were analyzed in an attempt to ascer-
tain the clinical findings and the bio-
logic hypothesis advanced by Arrieta’s
group. Average age was 64 years, 53%
were female, 39% had never been
smokers, 24% had been considerably
exposed to WS, and 23% of patients
had received erlotinib during some
stage of the disease. Nine of these
subjects had been exposed to WS and
27 had not been. Seven patients having
WSE had been smoking for an average
of 14 years.
Overall response rate to erlotinib
among patients with and without WSE
was 5% and 47% (p  0.0023), re-
spectively. PFS was also significantly
higher among patients who had no
history of WSE and who had received
erlotinib as first-line (p  0.037) and
second-line intervention (p  0.044).
Among patients having WSE history,
overall survival was 6.6 months (5.8 –
7.3) for those treated with erlotinib
and 15.4 months (10.7–20.1) for those
not treated with this compound (p 
0.0022) (Figure 1). Such difference
could be attributed to greater compro-
mise of performance status in the
group with WSE (61% Eastern Coop-
erative Oncology Group 2) due to
the marked deterioration of pulmonary
function.
In line with Arrieta’s proposal, a
multivariate analysis was carried out
for determining the factors influencing
mortality among patients with WSE.
Only performance status (p  0.053)
and gender (p  0.044) were seen to
be significant. Our data did not support
the findings described by Arrieta et al.,
highlighting the need for more consis-
tent studies in this field to be carried
out further.
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Results of several recently pub-
lished randomized trials (RTs), suggest
that non-small cell lung cancer (NSCLC)
with different histologic patterns may
respond differently to various treatment
modalities and thus may represent dif-
ferent disease entities. In a phase III RT
comparing pemetrexed-cisplatin versus
gemcitabine-cisplatin for previously un-
treated advanced NSCLC, it was ob-
served that among patients with adenocar-
cinoma, overall survival was statistically
superior for pemetrexed compared with
gemcitabine (12.6 versus 10.9 months;
hazards ratio [HR]  0.84; 95% CI 
0.71–0.99; p  0.031) while the reverse
was seen with squamous histology (9.4
versus 10.8 months; HR  1.23; 95%
CI  1.00–1.51; p  0.05).1 Nonsqua-
mous histology (as a group) had results
similar to adenocarcinoma.1 Differences
in progression free survival based on
histology have also been observed in
other RTs using third-generation plati-
num-based doublets for chemo-naive
patients with advanced NSCLC.2,3 Even
in the second line setting, pemetrexed
has been demonstrated to result in supe-
rior median overall survival and pro-
gression free survival for patients with
adenocarcinoma.4 However, for squamous
or large-cell histology, the drug fared no
better than placebo.4 An individual pa-
tient data meta-analysis involving 2968
patients from 9 RTs compared the effi-
cacy of cisplatin versus carboplatin when
used in first line chemotherapy for ad-
vanced NSCLC.5 Here also, carboplatin
was associated with increased mortality
for nonsquamous histology (HR 1.12;
95% CI  1.01–1.23).5
In addition, there is evidence to
suggest that vascular endothelial growth
factor receptor antagonists and tyrosine
kinase inhibitors seem to exert benefi-
cial effects predominantly in patients
with adenocarcinoma and nonsquamous
histologic types. Bevacizumab has in
fact been shown to be detrimental in
squamous histology. Squamous histol-
ogy remains a favorable prognostic
factor for patients undergoing lung re-
sectional surgery in both prospective
and retrospective studies. The con-
verse has, however, been observed in
unresectable disease. Thus, besides
being an important predictive factor
for different therapeutic modalities,
histologic type remains an important
prognostic factor as well.
With the growing body of evi-
dence to suggest that NSCLC is a
heterogeneous disease, an important
question that arises is that are we still
justified in clubbing all the different
histologic types as one disease entity?
Identification of genomic, proteomic
and/or pharmacogenomic differences
between different histologic patterns
could be helpful in practicing ‘person-
alized medicine.’ However, carrying
out such kind of analyses for each
patient is usually not possible in health
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FIGURE 1. Overall survival in patients treated with erlotinib.
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